Demant recalls cochlear implants – will cost up to EUR 13.4m in 2021, with more consequences for 2022

Oticon Medical, the surgical division of hearing aid group Demant, has located a performance issue in a number of non-implanted Neuro Zti chochlear implants, and the company sees no other option than to immediately withdraw the product from the market.

Photo: Demant / PR

Bad things often happen in threes, and they just keep coming for hearing aid manufacturer Demant. First, the company was hit by a cyber attack which effectively shut down the company for weeks, then the pandemic hit, and now Oticon Medical, the sugical division at Demant, is experiencing headwind.

On Thursday, Demant reports that its surgical branch has identified serious performance issues in 28 implanted devices. As a consequence, Oticon Medical is recalling around 4000 non-implanted Neuro Zti devices.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs